Loading clinical trials...
Loading clinical trials...
RECTIV® is an ointment containing 0.4% nitroglycerin (NTG) for the treatment of moderate to severe pain associated with chronic anal fissure approved in June 2011 by the US Food and Drug Administratio...
Bring this clarity to your next appointment.
Keep all your medical notes and next steps in one place.
Lead Sponsor
Forest Laboratories
NCT06798155 · Hemorrhoid, Anal Fistulas, and more
NCT06803550 · Anal Fistula, Anal Fissure Chronic, and more
NCT06859554 · Acute Anal Fissure, Anal Pain, and more
NCT06617026 · Anal Fissure Chronic
NCT05409820 · Anorectal Diseases, Hemorrhoids, and more
Children's Hospital
Los Angeles, California
Advanced Medical Research Center
Miami, Florida
Arnold Palmer Hospital for Children
Orlando, Florida
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions